The effect of fondaparinux versus enoxaparin in the survival of a congested skin flap in a rabbit model

Thomas L. Chung, Luther H. Holton, Ronald P. Silverman

Research output: Contribution to journalArticle

Abstract

Background: The purpose of this study was to evaluate the effects of fondaparinux, a selective antithrombin III agonist, in comparison to the low-molecular-weight heparin enoxaparin in the survival of a congested skin flap. Materials and Methods: Eighteen axial-pattern auricular flaps were performed on rabbits using a well-described congested flap model. Animals were randomized into 2 treatment groups, enoxaparin (n = 6) and fondaparinux (n = 6), and a control group (n = 6) that received no treatment. Skin flap survival area was measured post-operatively at 7 and 14 days. Results: The groups that received fondaparinux and enoxaparin had similar mean flap survival areas and were not statistically different. However, both treatment groups significantly increased flap survival compared with controls (P <0.014). Conclusions: Fondaparinux, like enoxaparin, significantly improves survival of congested flaps in rabbits. Its use instead of enoxaparin may be warranted, given that it eliminates the risk of heparin-induced thrombocytopenia. Further study in humans is warranted.

Original languageEnglish (US)
Pages (from-to)312-315
Number of pages4
JournalAnnals of Plastic Surgery
Volume56
Issue number3
DOIs
StatePublished - Mar 2006
Externally publishedYes

Fingerprint

Enoxaparin
Rabbits
Skin
Survival
Antithrombin III
Low Molecular Weight Heparin
Thrombocytopenia
Heparin
fondaparinux
Control Groups

Keywords

  • Enoxaparin
  • Flap congestion
  • Flap survival
  • Fondaparinux

ASJC Scopus subject areas

  • Surgery

Cite this

The effect of fondaparinux versus enoxaparin in the survival of a congested skin flap in a rabbit model. / Chung, Thomas L.; Holton, Luther H.; Silverman, Ronald P.

In: Annals of Plastic Surgery, Vol. 56, No. 3, 03.2006, p. 312-315.

Research output: Contribution to journalArticle

Chung, Thomas L. ; Holton, Luther H. ; Silverman, Ronald P. / The effect of fondaparinux versus enoxaparin in the survival of a congested skin flap in a rabbit model. In: Annals of Plastic Surgery. 2006 ; Vol. 56, No. 3. pp. 312-315.
@article{95069144511c474f807ae6f8e9cb95bd,
title = "The effect of fondaparinux versus enoxaparin in the survival of a congested skin flap in a rabbit model",
abstract = "Background: The purpose of this study was to evaluate the effects of fondaparinux, a selective antithrombin III agonist, in comparison to the low-molecular-weight heparin enoxaparin in the survival of a congested skin flap. Materials and Methods: Eighteen axial-pattern auricular flaps were performed on rabbits using a well-described congested flap model. Animals were randomized into 2 treatment groups, enoxaparin (n = 6) and fondaparinux (n = 6), and a control group (n = 6) that received no treatment. Skin flap survival area was measured post-operatively at 7 and 14 days. Results: The groups that received fondaparinux and enoxaparin had similar mean flap survival areas and were not statistically different. However, both treatment groups significantly increased flap survival compared with controls (P <0.014). Conclusions: Fondaparinux, like enoxaparin, significantly improves survival of congested flaps in rabbits. Its use instead of enoxaparin may be warranted, given that it eliminates the risk of heparin-induced thrombocytopenia. Further study in humans is warranted.",
keywords = "Enoxaparin, Flap congestion, Flap survival, Fondaparinux",
author = "Chung, {Thomas L.} and Holton, {Luther H.} and Silverman, {Ronald P.}",
year = "2006",
month = "3",
doi = "10.1097/01.sap.0000198550.72815.72",
language = "English (US)",
volume = "56",
pages = "312--315",
journal = "Annals of Plastic Surgery",
issn = "0148-7043",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - The effect of fondaparinux versus enoxaparin in the survival of a congested skin flap in a rabbit model

AU - Chung, Thomas L.

AU - Holton, Luther H.

AU - Silverman, Ronald P.

PY - 2006/3

Y1 - 2006/3

N2 - Background: The purpose of this study was to evaluate the effects of fondaparinux, a selective antithrombin III agonist, in comparison to the low-molecular-weight heparin enoxaparin in the survival of a congested skin flap. Materials and Methods: Eighteen axial-pattern auricular flaps were performed on rabbits using a well-described congested flap model. Animals were randomized into 2 treatment groups, enoxaparin (n = 6) and fondaparinux (n = 6), and a control group (n = 6) that received no treatment. Skin flap survival area was measured post-operatively at 7 and 14 days. Results: The groups that received fondaparinux and enoxaparin had similar mean flap survival areas and were not statistically different. However, both treatment groups significantly increased flap survival compared with controls (P <0.014). Conclusions: Fondaparinux, like enoxaparin, significantly improves survival of congested flaps in rabbits. Its use instead of enoxaparin may be warranted, given that it eliminates the risk of heparin-induced thrombocytopenia. Further study in humans is warranted.

AB - Background: The purpose of this study was to evaluate the effects of fondaparinux, a selective antithrombin III agonist, in comparison to the low-molecular-weight heparin enoxaparin in the survival of a congested skin flap. Materials and Methods: Eighteen axial-pattern auricular flaps were performed on rabbits using a well-described congested flap model. Animals were randomized into 2 treatment groups, enoxaparin (n = 6) and fondaparinux (n = 6), and a control group (n = 6) that received no treatment. Skin flap survival area was measured post-operatively at 7 and 14 days. Results: The groups that received fondaparinux and enoxaparin had similar mean flap survival areas and were not statistically different. However, both treatment groups significantly increased flap survival compared with controls (P <0.014). Conclusions: Fondaparinux, like enoxaparin, significantly improves survival of congested flaps in rabbits. Its use instead of enoxaparin may be warranted, given that it eliminates the risk of heparin-induced thrombocytopenia. Further study in humans is warranted.

KW - Enoxaparin

KW - Flap congestion

KW - Flap survival

KW - Fondaparinux

UR - http://www.scopus.com/inward/record.url?scp=33646093038&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646093038&partnerID=8YFLogxK

U2 - 10.1097/01.sap.0000198550.72815.72

DO - 10.1097/01.sap.0000198550.72815.72

M3 - Article

VL - 56

SP - 312

EP - 315

JO - Annals of Plastic Surgery

JF - Annals of Plastic Surgery

SN - 0148-7043

IS - 3

ER -